Healthcare Sales & Marketing Network News: Rydapt

Searching News Database: Rydapt

HSMN NewsFeed - 19 May 2020
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States
Diagnostics Oncology FDA

HSMN NewsFeed - 30 Oct 2019
European Commission Approves Astellas' XOSPATA(TM) for Patients with Relapsed or Refractory Acute Myeloid Leukemia with Mutations Detected using Invivoscribe's LeukoStrat(R) CDx FLT3 Mutation Assay
Diagnostics Oncology Regulatory

HSMN NewsFeed - 28 Apr 2017
Invivoscribe(R) Receives FDA Approval for the LeukoStrat(R) CDx FLT3 Mutation Assay Companion Diagnostic Test for the Selection of Patients for Rydapt(R) and is the First Companion Diagnostic for AML
Diagnostics Personalized Medicine Oncology FDA

HSMN NewsFeed - 28 Apr 2017
Novartis Receives FDA Approval for Rydapt(R) in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia (AML) and Three Types of Systemic Mastocytosis (SM)
Biopharmaceuticals Oncology FDA

Return to NewsFeed

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.

FindReps - available on the Apple App Store for iPhone and iPad.